Jubilant Organosys has signed its second major CRAMS deal in a week. The company has signed a $33m, long-term contract with a US life sciences company. R Sankaraiah, Jubilant's Executive Director of Finance, said the company would book $250m orders in this year and $250m-$300m in the next three-four years.
Money Control
Tuesday 31 August 2010
Jubilant signs $33m CRAMS deal
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment